Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for N62509109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Capital World Investors 13G/A | 10.4% |
6/4/2026
Event 5/29/2026
|
||
|
RA Capital Management, L.P.
13G/A
|
9.9% |
5/15/2025
Event 3/31/2025
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
|
FMR LLC
13G/A
|
8.8% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 8.8% | |||
| Abigail P. Johnson | 8.8% | |||
|
Frazier Life Sciences X, L.P.
13D/A
|
8.7% |
9/22/2026
Event 9/18/2026
|
||
| Frazier Life Sciences X, L.P. | 6.1% | |||
| Frazier Lifesciences Sponsor LLC | 3.3% | |||
| FHMLS X, L.P. | 6.1% | |||
| FHMLS X, L.L.C. | 6.1% | |||
| Frazier Life Sciences Public Fund, L.P. | 8.7% | |||
| FHMLSP, L.P. | 8.7% | |||
| FHMLSP, L.L.C. | 8.7% | |||
| Frazier Life Sciences XI, L.P. | 1.1% | |||
| FHMLS XI, L.P. | 1.1% | |||
| FHMLS XI, L.L.C. | 1.1% | |||
| Frazier Life Sciences XII, L.P. | 0.3% | |||
| FHMLS XII, L.P. | 0.3% | |||
| FHMLS XII, L.L.C. | 0.3% | |||
| James N. Topper | 6.1% | |||
| Patrick J. Heron | 6.1% | |||
|
Forbion Capital Fund IV Cooperatief U.A.
13D/A
|
8.3% |
9/30/2025
Event 9/26/2025
|
||
| Forbion Capital Fund IV Cooperatief U.A. | 4.1% | |||
| Forbion IV Management B.V. | 4.1% | |||
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 4.1% | |||
| Forbion Growth Management B.V. | 4.1% | |||
| ForGrowth NAP B.V. | 8.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Viking Global Investors LP
13G/A
|
3.7% |
2/17/2026
Event 12/31/2025
|
||
| Viking Global Investors LP | 3.7% | |||
| Viking Global Opportunities Parent GP LLC | 3.7% | |||
| Viking Global Opportunities GP LLC | 2.5% | |||
| Viking Global Opportunities Portfolio GP LLC | 2.5% | |||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.5% | |||
| Viking Global Opportunities Drawdown GP LLC | 1.2% | |||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.2% | |||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.2% | |||
| Halvorsen Ole Andreas | 3.7% | |||
| Ott David C. | 3.7% | |||
| Shabet Rose Sharon | 3.7% | |||
|
BCLS II Investco, LP
13D/A
|
1.8% |
5/14/2026
Event 5/12/2026
|
||
| BCLS Fund III Investments, LP | 1.8% | |||
| Bain Capital Life Sciences Opportunities III, LP | 1.1% | |||
| Bain Capital Life Sciences Fund II, L.P. | 0.1% | |||
| BCLS II Investco, LP | 0.1% | |||
| BCLS II Equity Opportunities, LP | 0.3% | |||
| BCIP Life Sciences Associates, LP | <0.1% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 1.02 k | $24.7 k |
| 2026 Q2 | 213 | 124 M | $4.20 B |
| 2026 Q1 | 183 | 124 M | $3.97 B |
| 2025 Q4 | 200 | 119 M | $4.19 B |
| 2025 Q3 | 148 | 123 M | $3.49 B |
| 2025 Q2 | 141 | 116 M | $2.11 B |
| 2025 Q1 | 136 | 111 M | $2.28 B |
| 2024 Q4 | 144 | 98.6 M | $2.53 B |
| 2024 Q3 | 107 | 77.1 M | $1.28 B |
| 2024 Q2 | 98 | 72.3 M | $1.39 B |
| 2024 Q1 | 81 | 72.5 M | $1.71 B |
| 2023 Q4 | 38 | 63.6 M | $710 M |
| 2023 Q3 | 37 | 50.2 M | $464 M |
| 2023 Q2 | 31 | 48.8 M | $581 M |
| 2023 Q1 | 21 | 33.3 M | $445 M |
| 2022 Q4 | 15 | 33.5 M | $362 M |